Share this Page:
In this video interview, Professor Jens Bedke, Professor of Urology and Vice Chairman at the Department of Urology, University Hospital Tuebingen, Germany, discusses the advances in first-line treatment of renal cell carcinoma (RCC) from monotherapy, which has been the standard of care for the treatment of RCC, to combination therapies.
First-line treatment with a combination of an immune checkpoint inhibitor and a tyrosine kinase inhibitor (TKI) has been shown to improve outcomes in patients with clear-cell metastatic RCC, as compared with the current standard of care. Professor Bedke reviews the data and the impact on clinical practice in this interview with UroToday.